Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies

J Am Acad Dermatol. 2018 Jul;79(1):155-157. doi: 10.1016/j.jaad.2018.01.003. Epub 2018 Jan 4.
No abstract available

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Canada
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Substitution / methods*
  • Female
  • Follow-Up Studies
  • Humans
  • Interleukin-17 / administration & dosage
  • Interleukin-17 / antagonists & inhibitors*
  • Male
  • Middle Aged
  • Patient Safety
  • Psoriasis / drug therapy*
  • Psoriasis / pathology
  • Retrospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Interleukin-17
  • ixekizumab
  • secukinumab